PLYX
Polaryx Therapeutics, Inc.
Price Chart
Latest Quote
$1.90
+0.07 (+4.12%)
Current Price
| Previous Close | $1.82 |
| Open | $1.83 |
| Day High | $1.90 |
| Day Low | $1.82 |
| Volume | 8,558 |
Stock Information
| Shares Outstanding | 49.85M |
| Cash Equivalents | $11.54M |
| Net Income | $-6.85M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $94.46M |
| EPS (TTM) | $-0.14 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $79.18M |
| Income | $-6.85M |
| Book/sh | $0.22 |
| Cash/sh | $0.23 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 13.22 |
| Current Ratio | 13.53 |
Returns & Margins
| ROA | -42.52% |
| ROE | -96.56% |
Ownership
| Insider Ownership | 69.92% |
| Institutional Ownership | 4.40% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 8.65 |
Analyst Data
| Recommendation | none |
| Target Price | $7.50 |
Technical Indicators
| SMA20 | $1.97 |
| SMA50 | $2.02 |
| RSI | 32.74 |
| ATR | 0.1143 |
| Shares Float | 7.17M |
| Short Float | 0.67% |
| Short Ratio | 4.57 |
| Rel Volume | 0.30 |
Performance History
| Week | -0.79% |
| Month | -7.11% |
| Quarter | -4.77% |
| 6 Months | -66.34% |
| YTD | -94.59% |
| 10 Years | -94.59% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.89 | 8,558 |
| 2026-10-26 | $1.82 | 27,500 |
| 2026-10-23 | $1.85 | 43,000 |
| 2026-10-22 | $1.94 | 15,600 |
| 2026-10-21 | $1.94 | 13,300 |
| 2026-10-20 | $1.91 | 8,100 |
| 2026-10-19 | $1.92 | 29,300 |
| 2026-10-16 | $1.88 | 19,500 |
| 2026-10-15 | $1.95 | 42,600 |
| 2026-10-14 | $1.97 | 16,600 |
| 2026-10-13 | $1.94 | 14,800 |
| 2026-10-12 | $2.01 | 16,400 |
| 2026-10-09 | $2.00 | 11,000 |
| 2026-10-08 | $2.00 | 160,700 |
| 2026-10-07 | $2.09 | 11,400 |
| 2026-10-06 | $2.10 | 5,800 |
| 2026-10-05 | $2.07 | 40,100 |
| 2026-10-02 | $2.08 | 20,800 |
| 2026-10-01 | $2.02 | 59,000 |
| 2026-09-30 | $2.07 | 14,800 |
| 2026-09-29 | $2.07 | 31,000 |
| 2026-09-28 | $2.04 | 16,500 |
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on PLYX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Total Expenses | $7,821,000 | $4,352,000 | $3,781,000 |
| Other Income Expense | $-1,164,000 | $-26,004,000 | $2,000 |
| Operating Expense | $7,821,000 | $4,352,000 | $3,781,000 |
| General And Administrative Expense | $1,555,000 | $1,541,000 | $1,010,000 |
| Other Non Operating Income Expenses | - | $-26,004,000 | $2,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Normalized Income | $-7,821,000 | $-30,356,000 | $-3,779,000 |
| Net Income From Continuing And Discontinued Operation | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Total Operating Income As Reported | $-7,821,000 | $-4,352,000 | $-3,781,000 |
| Net Income Common Stockholders | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Net Income | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Net Income Including Noncontrolling Interests | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Net Income Continuous Operations | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Pretax Income | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Special Income Charges | $-1,164,000 | $0 | - |
| Operating Income | $-7,821,000 | $-4,352,000 | $-3,781,000 |
| Per Share | |||
| Diluted EPS | $-0.19 | $-0.64 | $-0.08 |
| Basic EPS | $-0.19 | $-0.64 | $-0.08 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,657,000 | $-4,352,000 | $-3,781,000 |
| Total Unusual Items | $-1,164,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-1,164,000 | $0 | - |
| EBITDA (Bullshit earnings) | $-7,821,000 | $-4,352,000 | $-3,781,000 |
| EBIT | $-7,821,000 | $-4,352,000 | $-3,781,000 |
| Diluted Average Shares | $47,343,297 | $47,343,297 | $47,343,297 |
| Basic Average Shares | $47,343,297 | $47,343,297 | $47,343,297 |
| Diluted NI Availto Com Stockholders | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Other Special Charges | $1,164,000 | - | - |
| Research And Development | $6,266,000 | $2,811,000 | $2,771,000 |
| Selling General And Administration | $1,555,000 | $1,541,000 | $1,010,000 |
| Other Gand A | $1,555,000 | $1,541,000 | $1,010,000 |
Fetched: 2026-10-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $4,565,000 | $4,712,000 | $1,277,000 |
| Total Assets | $5,170,000 | $5,001,000 | $2,315,000 |
| Total Non Current Assets | $0 | $0 | $0 |
| Current Assets | $5,170,000 | $5,001,000 | $2,315,000 |
| Other Current Assets | $27,000 | - | - |
| Prepaid Assets | $0 | $380,000 | $2,313,000 |
| Cash Cash Equivalents And Short Term Investments | $5,143,000 | $4,621,000 | $2,000 |
| Cash And Cash Equivalents | $5,143,000 | $4,621,000 | $2,000 |
| Debt | |||
| Net Debt | - | - | $126,000 |
| Total Debt | - | - | $128,000 |
| Current Debt And Capital Lease Obligation | - | - | $128,000 |
| Current Debt | - | - | $128,000 |
| Other Current Borrowings | - | - | $128,000 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $605,000 | $289,000 | $1,038,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 |
| Current Liabilities | $605,000 | $289,000 | $1,038,000 |
| Payables And Accrued Expenses | $584,000 | $288,000 | $909,000 |
| Payables | $561,000 | $202,000 | $823,000 |
| Accounts Payable | $470,000 | $72,000 | $473,000 |
| Equity | |||
| Common Stock Equity | $4,565,000 | $4,712,000 | $1,277,000 |
| Total Equity Gross Minority Interest | $4,565,000 | $4,712,000 | $1,277,000 |
| Stockholders Equity | $4,565,000 | $4,712,000 | $1,277,000 |
| Retained Earnings | $-99,635,000 | $-90,650,000 | $-60,294,000 |
| Other | |||
| Ordinary Shares Number | $47,343,297 | $47,343,297 | $47,343,297 |
| Share Issued | $47,343,297 | $47,343,297 | $47,343,297 |
| Tangible Book Value | $4,565,000 | $4,712,000 | $1,277,000 |
| Invested Capital | $4,565,000 | $4,712,000 | $1,405,000 |
| Working Capital | $4,565,000 | $4,712,000 | $1,277,000 |
| Total Capitalization | $4,565,000 | $4,712,000 | $1,277,000 |
| Additional Paid In Capital | $104,195,000 | $95,358,000 | $61,570,000 |
| Capital Stock | $5,000 | $4,000 | $1,000 |
| Common Stock | $5,000 | $4,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $21,000 | $1,000 | $1,000 |
| Current Accrued Expenses | $23,000 | $86,000 | $86,000 |
| Dueto Related Parties Current | $91,000 | $130,000 | $350,000 |
Fetched: 2026-10-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-3,944,000 | $-2,573,000 | $-173,000 |
| Operating Activities | |||
| Operating Cash Flow | $-3,944,000 | $-2,573,000 | $-173,000 |
| Cash Flow From Continuing Operating Activities | $-3,944,000 | $-2,573,000 | $-173,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $4,493,000 | $7,320,000 | $0 |
| Financing Cash Flow | $4,466,000 | $7,192,000 | $128,000 |
| Cash Flow From Continuing Financing Activities | $4,466,000 | $7,192,000 | $128,000 |
| Net Other Financing Charges | $-27,000 | - | - |
| Net Common Stock Issuance | $4,493,000 | $7,320,000 | $0 |
| Common Stock Issuance | $4,493,000 | $7,320,000 | $0 |
| Other | |||
| Repayment Of Debt | $0 | $-193,000 | $0 |
| Issuance Of Debt | $0 | $65,000 | $128,000 |
| End Cash Position | $5,143,000 | $4,621,000 | $2,000 |
| Beginning Cash Position | $4,621,000 | $2,000 | $47,000 |
| Changes In Cash | $522,000 | $4,619,000 | $-45,000 |
| Net Issuance Payments Of Debt | $0 | $-128,000 | $128,000 |
| Net Short Term Debt Issuance | $0 | $-128,000 | $128,000 |
| Short Term Debt Payments | $0 | $-193,000 | $0 |
| Short Term Debt Issuance | $0 | $65,000 | $128,000 |
| Change In Working Capital | $316,000 | $-621,000 | $369,000 |
| Change In Payables And Accrued Expense | $316,000 | $-621,000 | $294,000 |
| Change In Accrued Expense | $-43,000 | $0 | $-4,000 |
| Change In Payable | $359,000 | $-621,000 | $298,000 |
| Change In Account Payable | $398,000 | $-401,000 | $-52,000 |
| Stock Based Compensation | $4,725,000 | $2,400,000 | $3,237,000 |
| Net Income From Continuing Operations | $-8,985,000 | $-30,356,000 | $-3,779,000 |
| Change In Prepaid Assets | - | $0 | $75,000 |
| Other Non Cash Items | - | $26,004,000 | - |
Fetched: 2026-10-19